Nivolumab in Previously Untreated Melanoma withoutBRAFMutation | Zendy

Caroline Robert | Zendy; Georgina V. Long | Zendy; Benjamin Brady | Zendy; Caroline Dutriaux | Zendy; Michele Maio | Zendy; Laurent Mortier | Zendy; Jessica C. Hassel | Zendy; Piotr Rutkowski | Zendy; Catriona M. McNeil | Zendy; Ewa KalinkaWarzocha | Zendy; Kerry J. Savage | Zendy; Micaela Hernberg | Zendy; Célèste Lebbé | Zendy; J. Charles | Zendy; Catalin Mihalcioiu | Zendy; Vanna ChiarionSileni | Zendy; Cornelia Mauch | Zendy; Francesco Cognetti | Zendy; Ana Arance | Zendy; Henrik Schmidt | Zendy; Dirk Schadendorf | Zendy; Helen Gogas | Zendy; L. Lundgren-Eriksson | Zendy; Christine E. Horak | Zendy; Brian J. Sharkey | Zendy; Ian M. Waxman | Zendy; Victoria Atkinson | Zendy; Paolo A. Ascierto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab in Previously Untreated Melanoma withoutBRAFMutation

Author(s) -

Caroline Robert,

Georgina V. Long,

Benjamin Brady,

Caroline Dutriaux,

Michele Maio,

Laurent Mortier,

Jessica C. Hassel,

Piotr Rutkowski,

Catriona M. McNeil,

Ewa KalinkaWarzocha,

Kerry J. Savage,

Micaela Hernberg,

Célèste Lebbé,

J. Charles,

Catalin Mihalcioiu,

Vanna ChiarionSileni,

Cornelia Mauch,

Francesco Cognetti,

Ana Arance,

Henrik Schmidt,

Dirk Schadendorf,

Helen Gogas,

L. Lundgren-Eriksson,

Christine E. Horak,

Brian J. Sharkey,

Ian M. Waxman,

Victoria Atkinson,

Paolo A. Ascierto

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1412082

Subject(s) - dacarbazine , nivolumab , medicine , hazard ratio , confidence interval , melanoma , gastroenterology , odds ratio , placebo , oncology , chemotherapy , surgery , cancer , immunotherapy , pathology , cancer research , alternative medicine

Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research